Tulane Cancer Center and Tulane University

Past Years' awards and speakers 2003 Mauvernay Research Excellence Scholar: Charles S. Hemenway, M.D., Ph.D.
2003 Mauvernay Research Excellence Poster Presenters
2003 Mauvernay Research Excellence Seminar Invited Speakers

2004 Mauvernay Research Excellence Scholars: Tyler J. Curiel, M.D., M.P.H. and Weiping Zou, M.D., Ph.D.
2004 Mauvernay Research Excellence Poster Presenters
2004 Mauvernay Research Excellence Seminar Invited Speakers

About the award
Current year's seminar
Call for abstracts for the current year
Contact

Inaugural Mauvernay Research Excellence Scholar 2003

Charles S. Hemenway, M.D., Ph.D. has been named the Mauvernay Research Excellence Scholar for his research into new treatments for childhood leukemias. Dr. Hemenway was awarded a $5,000 prize as well as an etched crystal tribute commemorating this honor, and he delivered the Mauvernay Scholar address ("Rational Development of an Inhibitor of t(4;11) Leukemia") at the Inaugural Mauvernay Research Excellence Seminar, October 17, 2003.

---

Poster Presenters 2003

Eleven other Tulane faculty researchers each received a $500 prize, an etched crystal tribute, and presented their research in poster format with discussion at the seminar.

Lower row, center: Charles S. Hemenway, M.D., Ph.D.
Mauvernay Research Excellence Scholar 2003
Upper row, from left:

• "Reversing Tumor-Mediated Immune Suppression"
  Tyler J. Curiel, M.D.
  Associate Professor and Chief: Medicine: Hematology/Oncology
• "Novel Strategies for Targeting ErbB2/HER2/Neu Oncogenic Signaling in Cancer"
  Frank E. Jones, Ph.D.
  Assistant Professor of Structural and Cellular Biology (Anatomy)
• "Development of siRNA Based Therapeutics in Epstein Barr Virus Associated Malignancies"
  Erik K. Flemington, Ph.D.
  Associate Professor of Pathology
• "Cross-Talk Between the G-Protein Coupled Melatonin Signaling Pathway and Retinoic Acid Receptor Signaling Pathway Can Both Prevent the Development and Induce the Regression of Breast Cancer"
  Steven M. Hill, Ph.D.
  Professor of Structural and Cellular Biology (Anatomy)
• "Lysosomal Cystine Augmentation of Apoptosis to Treat Cancer"
  Jess G. Thoene, M.D.
  Director, Hayward Genetics Center
• "Ablation of p53 Function in the Lung Epithelium of Mice"
  Gilbert F. Morris, Ph.D.
  Associate Professor of Pathology
• "MEK5-Erk5 Signaling, a Novel Therapeutic Target Regulating Tumorigenesis and Invasion of Breast and Ovarian Carcinoma"
  Matthew E. Burow, Ph.D.
  Assistant Professor of Medicine: Hematology/Oncology

Lower row, from left:

• "Regulators of Telomeric Recombination Provide Novel Targets for Cancer Therapy"
  Arthur J. Lustig, Ph.D.
  Associate Professor of Biochemistry
• "A T-Type Calcium Channel Antagonist Inhibits Breast Cancer Cell Growth"
  Ming Li, Ph.D.
  Assistant Professor of Pharmacology
• Charles S. Hemenway, M.D., Ph.D., Mauvernay Research Excellence Scholar 2003
• "Tumor Immune Evasion and Dendritic Cells in Human Ovarian Carcinomas"
  Weiping Zou, M.D., Ph.D.
  Assistant Professor of Medicine: Hematology/Oncology
• "Recombinant Retroviruses as Tools for Identifying New Oncogenes Associated With Lymphoma"
  Laura S. Levy, Ph.D.
  Professor of Microbiology and Immunology

---

Invited Speakers 2003

• "Adoptive Immunotherapy with Costimulated T Cells"
  Carl H. June, M.D.
  Professor of Pathology and Laboratory Medicine
  University of Pennsylvania School of Medicine
• "DNA Damage Responses in Cancer Causation and Treatment"
  Michael B. Kastan, M.D., Ph.D.
  Chairman of Hematology-Oncology
  St. Jude Children's Research Hospital, Memphis, Tennessee
• "Molecular Targeting of FLT3 as Novel Therapy for Leukemia"
  Donald Small, M.D., Ph.D.
  Associate Professor of Oncology: Pediatric Oncology
  Johns Hopkins University
• "The Complexity of Nuclear Receptor Action in Cancer Cells Provides Opportunities for New Drug Discovery"
  Donald P. McDonnell, Ph.D.
  Professor of Pharmacology and Cancer Biology
  Duke University Medical Center

Mauvernay Research Excellence Scholars 2004

Tyler J. Curiel, MD, MPH
Chief, Section of Hematology and Medical Oncology
"A Novel Reagent to Deplete Regulatory T Cells Improves Immunity and Enhances Tumor Clearance in Human Cancer"

Weiping Zou, MD, PhD
Assistant Professor, Department of Medicine, Section of Hematology and Medical Oncology
"Identification of a Novel Immunotherapeutic Target in Patients with Ovarian Cancers"

Dr. Curiel and Dr. Zou have been named the Mauvernay Research Excellence Scholars for 2004. They will each be awarded a $2,500 prize as well as an etched crystal tribute commemorating this honor, and they will jointtly deliver the Mauvernay Scholar address ("Cancer: When Bad Things Happen to Good Cells") at the Mauvernay Research Excellence Seminar, October 8, 2003.

---

2004 Poster Presenter Honorees

• Asim B. Abdel-Mageed, D.V.M., Ph.D.
  Associate Professor, Department of Urology
  "In Vivo Gene Expression Profile Analysis of Prostate Cancer by LCM, SSH, and Custom cDNA Microarray: Identification of hnRNP-H1 and SAFB2 as Possible Biomarkers/Therapeutic Targets for Disease Progression in African American Patients"
• Barbara S. Beckman, Ph.D.
  Professor, Department of Pharmacology
  "Novel Ceramide Analogs as Potential Chemotherapeutic Agents in Breast Cancer"
• Matthew E. Burow, Ph.D.
  Assistant Professor, Department of Medicine, Section of Hematology and Medical Oncology
  "MEK5-Erk5 Signaling, a Novel Therapeutic Target Regulating Tumorigenesis and Invasion of Breast and Ovarian Carcinoma"
• Srikanta Dash, Ph.D.
  Associate Professor, Department of Pathology
  "Intracellular Immunization with a Genetically Engineered Human Antibody Clone Inhibits Helicase Activity, Protein Expression and Replication of Hepatitis C Virus"
• Prescott Deininger, Ph.D.
  Marguerite Main Zimmerman Chair in Basic Cancer Research
  Professor, Environmental Health Sciences
  Associate Director for Basic Science Programs, Tulane Cancer Center
  "Mobile Elements and Human Genetic Instability"
• Erik Flemington, Ph.D.
  Associate Professor, Department of Pathology
  "Identification of Potential Therapeutic Targets for EBV Associated Malignancies"
• Timothy Hammond, M.D.
  Professor, Department of Medicine, Section of Nephrology
  "Megalin Subunits Prevent Cisplatin Nephrotoxicity"
• Frank Jones, Ph.D.
  Assistant Professor, Department of Biochemistry
  "ERBB4 is a Tumor Suppressor That Selectively Induces Cell-Killing of Cancer But Not Normal Cells"
• Laura S. Levy, Ph.D.
  Professor, Department of Microbiology and Immunology
  "Identification of Potential Therapeutic Targets that Regulate Growth of AIDS-Related Lymphoma"
• Cindy A. Morris, Ph.D.
  Associate Professor, Department of Microbiology and Immunology
  "The Role of P-TEFb in Tumor-Associated Angiogenesis"

---

Invited Speakers 2004

• "Translating Laboratory Discovery to Patient Care: Novel Markers and Targets in GI Malignancies"
  Scott A. Waldman, MD, PhD, FCP
  Samuel M.V. Hamilton Professor of Medicine and Professor of Biochemistry and Molecular Pharmacology
  Director of the Division of Clinical Pharmacology
  Thomas Jefferson University
• "Imatinib as a Paradigm of Targeted Cancer Therapies"
  Brian J. Druker, M.D.
  Investigator, Howard Hughes Medical Institute Professor of Medicine, Oregon Health & Science University
• "Double-Strand Break Repair and Genomic Integrity"
  Maria Jasin, PhD
  Member, Molecular Biology Program
  Memorial Sloan-Kettering Cancer Center
• "Protein Folding and Cancer: The Hsp90 Chaperone as a Therapeutic Target"
  Neal Rosen, MD, PhD
  Member, Department of Medicine and Cell Biology
  Memorial Sloan-Kettering Cancer Center

See also: current's years Mauvernay Research Excellence Seminar

This page is http://www.som.tulane.edu/cancer/mauvernaypast.html
This page was last updated on

---

Return to the top of this page.
Return to the Tulane Cancer Center homepage.

Calendars Clinical Trials Faculty Links Location News

Search Site index
See also: listing of Research Grants and Funding Opportunities

---

Tulane Cancer Center, Box SL-68
1430 Tulane Avenue
New Orleans, Louisiana 70112-2699
(504) 988-6060, fax (504) 988-6077
http://www.som.tulane.edu/cancer